Author

Manuel Barreiro de Acosta

THE JAK-3 AND TYK-2 / STAT PATHWAYS ARE ACTIVATED IN MODERATE TO SEVERE ULCERATIVE COLITIS
THE JAK-3 AND TYK-2 / STAT PATHWAYS ARE ACTIVATED IN MODERATE TO SEVERE ULCERATIVE COLITIS

Manuel Barreiro de Acosta  et al.

INFLUENCE OF THE INTERVAL OF TIME BETWEEN ANTI-TNF AND VEDOLIZUMAB OR USTEKINUMAB IN THE RESPONSE TO TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
INFLUENCE OF THE INTERVAL OF TIME BETWEEN ANTI-TNF AND VEDOLIZUMAB OR USTEKINUMAB IN THE RESPONSE TO TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Manuel Barreiro de Acosta  et al.

DO PSEUDOPOLYPS INCREASE FECAL CALPROTECTIN IN PATIENTS WITH ULCERATIVE COLITIS IN CLINICAL AND ENDOSCOPIC REMISSION?
DO PSEUDOPOLYPS INCREASE FECAL CALPROTECTIN IN PATIENTS WITH ULCERATIVE COLITIS IN CLINICAL AND ENDOSCOPIC REMISSION?

Manuel Barreiro de Acosta  et al.

EFFICACY AND SAFETY OF RE-INDUCTION WITH INTRAVENOUS USTEKINUMAB IN PATIENTS WITH CROHN´S DISEASE AND LOSS OF RESPONSE TO THAT DRUG
EFFICACY AND SAFETY OF RE-INDUCTION WITH INTRAVENOUS USTEKINUMAB IN PATIENTS WITH CROHN´S DISEASE AND LOSS OF RESPONSE TO THAT DRUG

Manuel Barreiro de Acosta  et al.

RISK OF PROGRESSION OF PRECLINICAL ULCERATIVE COLITIS
RISK OF PROGRESSION OF PRECLINICAL ULCERATIVE COLITIS

Manuel Barreiro de Acosta  et al.

EFFECTIVENESS OF THIRD-CLASS BIOLOGIC TREATMENT IN CROHN´S DISEASE: A MULTI-CENTER RETROSPECTIVE COHORT STUDY
EFFECTIVENESS OF THIRD-CLASS BIOLOGIC TREATMENT IN CROHN´S DISEASE: A MULTI-CENTER RETROSPECTIVE COHORT STUDY

Manuel Barreiro de Acosta  et al.

THE INFLUENCE OF PREOPERATIVE MEDICATIONS IN SURGICAL COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE IN SPAIN: A MULTICENTER STUDY OF GETECCU
THE INFLUENCE OF PREOPERATIVE MEDICATIONS IN SURGICAL COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE IN SPAIN: A MULTICENTER STUDY OF GETECCU

Manuel Barreiro de Acosta  et al.

VACCINATION STRATEGIES IN INFLAMMATORY BOWEL DISEASE PATIENTS: PERSPECTIVE OF PHYSICIANS AND PATIENTS.
VACCINATION STRATEGIES IN INFLAMMATORY BOWEL DISEASE PATIENTS: PERSPECTIVE OF PHYSICIANS AND PATIENTS.

Manuel Barreiro de Acosta  et al.

ADHERENCE TO VACCINATION RECOMMENDATIONS IN INFLAMMATORY BOWEL DISEASE PATIENT: A LONG WAY FOR IMPROVING.
ADHERENCE TO VACCINATION RECOMMENDATIONS IN INFLAMMATORY BOWEL DISEASE PATIENT: A LONG WAY FOR IMPROVING.

Manuel Barreiro de Acosta  et al.

SARS-COV-2 VACCINE ACCEPTANCE AMONG GASTROENTEROLOGIST AND INFLAMMATORY BOWEL DISEASE PATIENTS: VACUNEII PROJECT
SARS-COV-2 VACCINE ACCEPTANCE AMONG GASTROENTEROLOGIST AND INFLAMMATORY BOWEL DISEASE PATIENTS: VACUNEII PROJECT

Manuel Barreiro de Acosta  et al.

COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY
COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY

Manuel Barreiro de Acosta  et al.

INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU
INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU

Manuel Barreiro de Acosta  et al.

MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY
MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY

Manuel Barreiro de Acosta  et al.

INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)
INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)

Manuel Barreiro de Acosta  et al.

Item 1 - 14 / 14
1